Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Noble Acquires Property with Significant Uranium, Rare Earth, Phosphorus & Silver Mineralization (click to learn more) V.AFM: Record Fy2024 & Q4 ‘24 Tin Production Fy2025 Production Guidance Exploration Success (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Opthea Spon American Depositary Receipts Representing 8 Ord Shs OPT

Alternate Symbol(s):  CKDXF

Healthcare Biotechnology
Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OPT)

Opthea to Host Investor Days in New York and Australia

GlobeNewswire 11 days ago

Opthea Announces Publication in Diabetic Macular Edema

GlobeNewswire 12 days ago

Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 19, 2024

Opthea's Wet AMD Program to be Featured at FLORetina 2024

GlobeNewswire November 26, 2024

Opthea to Participate in Citi 2024 Global Healthcare Conference

GlobeNewswire November 25, 2024

Opthea Appoints Kathy Connell to Board of Directors

GlobeNewswire November 15, 2024

Opthea's Wet AMD Program Featured at Ophthalmology Events

GlobeNewswire November 12, 2024

Opthea to Participate in November Investor Conferences

GlobeNewswire November 4, 2024

Opthea Files Notice of Annual General Meeting

GlobeNewswire October 16, 2024
View More News ››

Opinion & Analysis (NDAQ:OPT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OPT)

Opthea's Wet AMD Program to be Featured at FLORetina 2024

BREAKING NEWS: $OPT Opthea's Wet AMD Program to be Featured at FLORetina 2024MELBOURNE, Australia, and Princeton, N.J., Nov. 26...
whytestocks - November 26, 2024

Opthea Appoints Kathy Connell to Board of Directors

JUST IN: $OPT Opthea Appoints Kathy Connell to Board of DirectorsMs. Connell is a commercial executive with business development...
whytestocks - November 15, 2024
View more Bullboard ››

Visionstate Corp.

Visionstate Corp.

Visionstate Corp.is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »